ES2097497T3 - Biocatalizador dirigido a agentes patogenos. - Google Patents

Biocatalizador dirigido a agentes patogenos.

Info

Publication number
ES2097497T3
ES2097497T3 ES93907298T ES93907298T ES2097497T3 ES 2097497 T3 ES2097497 T3 ES 2097497T3 ES 93907298 T ES93907298 T ES 93907298T ES 93907298 T ES93907298 T ES 93907298T ES 2097497 T3 ES2097497 T3 ES 2097497T3
Authority
ES
Spain
Prior art keywords
pathogenicity
pathogen
biocatalizer
aimed
binding agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93907298T
Other languages
English (en)
Inventor
Roberto Crea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CREAGEN Inc
Original Assignee
CREAGEN Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CREAGEN Inc filed Critical CREAGEN Inc
Application granted granted Critical
Publication of ES2097497T3 publication Critical patent/ES2097497T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

ESTA INVENCION PERTENECE A BIOCATALIZADORES QUE SE APLICAN ESPECIFICAMENTE A AGENTES PATOGENOS DE ENLACE, TALES COMO VIRUS, Y A DEGRADAR COMPONENTES DE PATOGENOS, CON OBJETO DE ANULAR SU PATOGENICIDAD, Y A METODOS PARA EVITAR O TRATAR INFECCIONES DEBIDAS A ORGANISMOS PATOGENOS. LOS BIOCATALIZADORES COMPRENDEN UN AGENTE AGLUTINANTE, QUE ESPECIFICAMENTE ENLAZA UN COMPONENTE EXTERNO DE UN PATOGENO, POR EJEMPLO LA PROTEINA DE REVESTIMIENTO VIRAL GP120 DEL HUMAN INMUNODEFICIENCY VIRUS (VIRUS DE INMUNODEFICIENCIA HUMANA), Y UNA MITAD CATALITICA QUE DEGRADA UN COMPONENTE DEL PATOGENO, CON LO QUE SE ANULA SU PATOGENICIDAD. EL AGENTE AGLUTINANTE Y LA MITAD CATALITICA SE ENLAZAN MEDIANTE ELEMENTOS DE ENLACE QUIMICOS O TECNICAS INDUSTRIALES GENETICAS.
ES93907298T 1992-03-06 1993-03-05 Biocatalizador dirigido a agentes patogenos. Expired - Lifetime ES2097497T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84780092A 1992-03-06 1992-03-06

Publications (1)

Publication Number Publication Date
ES2097497T3 true ES2097497T3 (es) 1997-04-01

Family

ID=25301545

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93907298T Expired - Lifetime ES2097497T3 (es) 1992-03-06 1993-03-05 Biocatalizador dirigido a agentes patogenos.

Country Status (9)

Country Link
EP (1) EP0629244B1 (es)
JP (1) JPH07504571A (es)
AT (1) ATE143053T1 (es)
AU (1) AU680407B2 (es)
CA (1) CA2130832C (es)
DE (1) DE69304899T2 (es)
DK (1) DK0629244T3 (es)
ES (1) ES2097497T3 (es)
WO (1) WO1993018162A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0782626A1 (en) * 1994-09-19 1997-07-09 Rijkslandbouwuniversiteit Wageningen Gene constructs encoding crop-protecting agents, as well as transformed plants containing and expressing such constructs, and methods of controlling plague organisms and pathogens in crops
US6399355B1 (en) * 1995-06-07 2002-06-04 The Trustees Of Columbia University In The City Of New York Non-naturally occurring targeted lipolytic compounds and related compositions and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010015A1 (en) * 1989-02-23 1990-09-07 Seragen, Inc. Chimeric toxin
CA2051107A1 (en) * 1989-04-25 1990-10-26 William N. Sun Antibodies specific for cd4-binding domain of hiv
CA2071969A1 (en) * 1989-12-22 1991-06-23 John R. Murphy Hybrid molecules having translocation region and cell-binding region
AU642980B2 (en) * 1990-03-21 1993-11-04 Quest International B.V. Ultilization of enzymes

Also Published As

Publication number Publication date
EP0629244A1 (en) 1994-12-21
DE69304899D1 (de) 1996-10-24
EP0629244B1 (en) 1996-09-18
ATE143053T1 (de) 1996-10-15
WO1993018162A1 (en) 1993-09-16
CA2130832C (en) 2002-08-06
JPH07504571A (ja) 1995-05-25
AU3795093A (en) 1993-10-05
DK0629244T3 (es) 1997-03-17
AU680407B2 (en) 1997-07-31
CA2130832A1 (en) 1993-09-16
DE69304899T2 (de) 1997-03-13

Similar Documents

Publication Publication Date Title
EA199700215A1 (ru) Защита от вирусных инфекций путем колонизации слизистых оболочек генетически модифицированными бактериями
ES2087156T3 (es) Metodos para la inactivacion de virus en composiciones farmaceuticas contaminadas por virus.
AP2000001942A0 (en) Use of organophosphoric compounds for the therapeutic and preventative treatment of infections.
EA200201279A1 (ru) Способы и композиции для лечения вирусного гепатита c
ATE405279T1 (de) Immobilisierung und stabilisierung von viren
IL157041A0 (en) Monoclonal antibodies to the clfa protein and method of use in treating and preventing infections
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
WO2000053213A3 (en) Cyanovirin conjugates, matrix-anchored cyanovirin and anti-cyanovirin antibody, and related compositions and methods of use
ATE298741T1 (de) Polyaromatische verbindungen zur behandlung von herpes-infektionen
PT726758E (pt) Peptidos para induzir respostas de linfocitos t citotoxicos ao virus da hepatite b
CA2192512A1 (en) Nm03 antibody materials and methods
FR2760367B1 (fr) Composition vaccinale destinee a la prevention ou au traitement des hepatites c
PT1200126E (pt) Utilização de anticorpos monoclonais específicos de cd28 para a preparação de uma composição farmacêutica para o tratamento de infecções virais
CA2218561A1 (en) Compounds and methods of use to treat infectious diseases
BR0109164A (pt) Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos
ES2097497T3 (es) Biocatalizador dirigido a agentes patogenos.
TR200101841T2 (tr) Enfeksiyonlardan korunmak ve enfeksiyon tedavisi için bifosfonatların kullanılmaları
EP0600396A3 (en) Gut protozoan vaccines.
ATE408410T1 (de) Kombinationstherapie zur behandlung von hepatitis b infektionen
ES2159287T3 (es) Peptidos hemorreguladores.
FR2646607B1 (fr) Anticorps monoclonaux anti-b2 microglobuline
ID23516A (id) Alat-alat pengantaran obat dan metoda-metoda untuk perlakuan infeksi-infeksi yang disebabkan oleh virus dan mikroba dan sindrom-sindrom yang membahayakan.
PH27309A (en) Prevention of glycoprotein enveloped virus infectivity by quinolyl-and isoquinolyloxazone-2-ones
EP1334131A4 (en) MONOCLONAL ANTIBODIES AGAINST THE MAP PROTEIN AND METHOD OF USING THE SAME IN THE TREATMENT OR PREVENTION OF INFECTIONS

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 629244

Country of ref document: ES